



LKT Laboratories, Inc.

ABT-199

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID A0776

CAS No. 1257044-40-8

Chemical Name

Synonym GDC-0199, Venectoclax

Formula C₄₅H₅₀ClN₇O₇S

Formula Wt. 868.44

Melting Point


Purity ≥98%

Solubility DMSO 100 mg/mL
warmed (115.14 mM)
Water Insoluble
Ethanol Insoluble

Store Temp 4° C

Ship Temp Ambient

Description ABT-199 is a BH3 mimetic that inhibits Bcl-2 but does not affect Bcl-xl. ABT-199 exhibits anticancer chemotherapeutic activity, inducing Bim-mediated apoptosis in chronic lymphocytic leukemia (CLL) cells. ABT-199 also induces cell death and inhibits tumor growth in acute myelogenous leukemia (AML) models in vitro, ex vivo, and in vivo. ABT-199 is currently under examination as a potential treatment for CLL.



Bulk quantities available upon request

Product ID	Size
A0776	1 mg
A0776	5 mg
A0776	10 mg

References Khaw SL, Mérito D, Anderson MA, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. *Leukemia*. 2014 Jan 9. [Epub ahead of print]. PMID: 24402163.

Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia. *Cancer Discov*. 2014 Feb 13. [Epub ahead of print]. PMID: 24346116.

Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. *Blood*. 2013 Mar 21;121(12):2285-8. PMID: 23341542.

Souers AJ, Levenson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nat Med*. 2013 Feb;19(2):202-8. PMID: 23291630.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.